Amygdala responses to quetiapine XR and citalopram treatment in major depression: the role of 5-HTTLPR-S/Lg polymorphisms

Autor:	Darren L. Clark, Ismael Gaxiola-Valdez, Glenda MacQueen, N. Torben Bech-Hansen, Ashley Burgess, Anne Kemp, Rajamannar Ramasubbu, Vaibhav A. Diwadkar, Bradley G. Goodyear, Jane A. Foster, Filomeno Cortese
Rok vydání:	2016
Předmět:	Oncology medicine.medical_specialty Citalopram Amygdala 03 medical and health sciences 0302 clinical medicine Internal medicine mental disorders medicine Pharmacology (medical) Serotonin transporter Depression (differential diagnoses) biology medicine.disease 030227 psychiatry Psychiatry and Mental health medicine.anatomical_structure Neurology 5-HTTLPR biology.protein Antidepressant Major depressive disorder Quetiapine Neurology (clinical) Psychology 030217 neurology & neurosurgery medicine.drug Clinical psychology
Zdroj:	Human Psychopharmacology: Clinical and Experimental. 31:144-155
ISSN:	0885-6222
Popis:	Objectives Genotype and drug pharmacology may contribute to variations in brain response to antidepressants. We examined the impact of two antidepressants with differential actions on serotonin transporter and the 5-HHTLPR-S/Lg polymorphisms on amygdala responses in major depressive disorder (MDD). Methods Caucasians with MDD were given either citalopram or quetiapine extended release for 8 weeks. Patients were genotyped for 5-HTTLPR. Clinical efficacy was assessed using the Hamilton Depression Rating Scale. fMRI responses to negative emotional faces were acquired at baseline, week 1 and week 8. The outcome measure was change in amygdala responses at week 8. Results Citalopram had no effect on amygdala responses in MDD patients with S/Lg alleles at weeks 1 and 8 compared with baseline, whereas it induced changes in amygdala responses in LL homozygotes. By contrast, quetiapine decreased amygdala responses at both time points in S/Lg carriers, and changes in amygdala responses at week 8 correlated with a reduction in depression scores. The small number of LL homozygotes in quetiapine group was a limitation. Efficacy of both treatments was comparable. Conclusions These preliminary data suggest that pharmacological mechanisms and genetics need to be considered in the development of neuroimaging markers for the evaluation of antidepressant treatments. Copyright © 2016 John Wiley & Sons, Ltd.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::cb9cd83411fa5ed548b9492540e8202d https://doi.org/10.1002/hup.2521 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.